|
|
 |
|
Viewing report
|
|
|
|
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Decision Resources, Inc., Sep 2009, Pages: 24
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses and finding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures.
Questions Answered in This Report
In recent years, drug developers have invested heavily in various R&D technologies.
- Is this investment increasing R&D productivity?
- What technology strategies are most promising?
- What new approaches are pharmaceutical companies using to access enabling technologies for drug discovery?
Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
- What steps are leading companies taking to change R&D?
- What structures and strategies have already been implemented within Big Pharma R&D organizations?
- Can pharmaceutical companies replicate the innovation of biotech companies by reforming R&D?
Biotech companies are an important source of novel technologies and drug candidates.
- How do acquisitions of and collaborations with biotech companies fit into Big Pharma’s R&D strategies?
- How can companies use business development activities to build up technological capabilities and pipelines?
Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.
- Which companies have recently formed innovative partnerships that include early-stage development?
- What are the key features of these arrangements?
- How do these ventures meet the strategic needs of both partners?
Scope
- Technology strategies: Use of high-throughput technologies and R&D productivity, biologics platforms, pharma-pharma ventures for enabling technology development.
- Organizational structures and strategies: Restructuring R&D, emulating biotech, case studies of R&D reorganization.
- Building R&D through business development: M&As, collaborations, R&D strategies.
- Pharma-pharma partnering: Strategic alliances among Big Pharma companies, Phase I co development collaboration, therapeutic area joint venture.
- Outsourcing R&D: China, India, potential advantages and disadvantages.
- Outlook for pharmaceutical R&D: Changing business models, personalized medicine, pursuing novel targets, collaboration, high-throughput strategies, translational medicine.
Customers who bought this item also bought
Innovative Partnering and Dealmaking Strategies
How Big Pharma's R&D Focus Is Changing
Strategies for Building Early-Stage Pharmaceutical Pipelines Through External Sources
State of the Pharmaceutical Industry 2011 - Industry Remodeling Activities
Value-Added Pharma: How to Accomplish the Impossible
Competitor Analysis - Cancer Antibodies in Early Clinical Development
Pharma's Changing Business Strategies: Five Deadly Pharma Sins
Dealmaking and Industry Outlook in Niche Metabolic Diseases
Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships
Big Pharma’s New Licensing Strategies
|
|
|
|
